Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study - Poll - MDSpire

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

  • By

  • Niels W. C. J. van de Donk

  • Nizar Bahlis

  • Luciano J. Costa

  • María-Victoria Mateos

  • Ajay K. Nooka

  • Aurore Perrot

  • Alfred L. Garfall

  • Pragya Thaman

  • Keqin Qi

  • Clarissa Uhlar

  • Katherine Chastain

  • Margaret Doyle

  • Saad Z. Usmani

  • October 21, 2024

  • 0 min

Share

Original Source(s)

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

  • by Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani

  • October 21, 2024

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma